City of Hope and CytoImmune Therapeutics Inc. have entered into worldwide exclusive license agreements to several patent applications related to methods to generate large numbers of fully functional natural killer (NK) cells derived from umbilical cord blood and compositions of chimeric receptors (CAR) for targeting NK cells to tumors.
[CytoImmune Therapeutics, Inc. (BusinessWire, Inc)]
6445218 nan items 1 apa default asc 1
Scientists focus on immune dysfunction in newly diagnosed chronic myeloid leukemia patients, and the role that tyrosine kinase inhibitors and other therapies have in restoring immune surveillance.
Human plasmacytoid dendritic cells produced high amounts of type I interferon when incubated with live cytomegalovirus-infected fibroblasts but not with free cytomegalovirus
6445218 QM7HPF9K items 1 apa default asc 1
Yun, T. J., Igarashi, S., Zhao, H., Perez, O. A., Pereira, M. R., Zorn, E., Shen, Y., Goodrum, F., Rahman, A., Sims, P. A., Farber, D. L., & Reizis, B. (2021). Human plasmacytoid dendritic cells mount a distinct antiviral response to virus-infected cells. Science Immunology, 6(58). https://doi.org/10.1126/sciimmunol.abc7302 Cite
Researchers showed that the N-terminal signal peptide was the major US9 functional domain targeting MICA*008 to proteasomal degradation.
6445218 3TCQ4Y68 items 1 apa default asc 1
Scientists describe a case of new-onset food anaphylaxis after cord blood transplantation (CBT) in an adult patient that demonstrated that post-CBT allergen-challenge was not a risk for long-term allergic sensitization, even in adult recipients.
[International Journal of Hematology]
6445212 TWF49HNK items 1 apa default asc 1
Scientists found that patients with early natural killer cell activation after PEG–IFN-α injection experienced greater liver inflammation, lysis of HBV-infected hepatocytes, and hepatitis B surface antigen decline than those without.
[Science Translational Medicine]
6445218 98V83KPK items 1 apa default asc 1
Nishio, A., Bolte, F. J., Takeda, K., Park, N., Yu, Z.-X., Park, H., Valdez, K., Ghany, M. G., & Rehermann, B. (2021). Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection. Science Translational Medicine, 13(587). https://doi.org/10.1126/scitranslmed.aba6322 Cite
Researchers report an essential cross-talk between CAR T cell subsets and the TME for tumor control in an immunocompetent mouse B cell lymphoma model of anti-CD19 CAR T cell therapy.
6445218 736KL2EX items 1 apa default asc 1
Boulch, M., Cazaux, M., Loe-Mie, Y., Thibaut, R., Corre, B., Lemaître, F., Grandjean, C. L., Garcia, Z., & Bousso, P. (2021). A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Science Immunology, 6(57). https://doi.org/10.1126/sciimmunol.abd4344 Cite
While acute myeloid leukemia represents an intuitive disease in which to investigate chimeric antigen receptor (CAR) based immunotherapies, key biological differences to B-cell malignancies have complicated progress to date.
IRF-1 induces miR-195 to suppress CHK1 protein expression. Both increased IRF-1 and decreased CHK1 upregulate cellular apoptosis and PD-L1 expression in HCC.
[British Journal of Cancer]
6606345 FXD6NJYL items 1 apa default asc 1
Yan, Y., Zheng, L., Du, Q., Cui, X., Dong, K., Guo, Y., & Geller, D. A. (2021). Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells. British Journal of Cancer, 1–11. https://doi.org/10.1038/s41416-021-01337-6 Cite
Exacis Biotherapeutics Inc., announced several important steps in the preclinical development of its ExaNK™ engineered NK cell-therapy candidates.
[Exacis Biotherapeutics Inc. (PR Newswire LLC.)]
6606345 nan items 1 apa default asc 1
Scientists focus on the use of engineered cells to treat glioblastoma, with an emphasis on data from the small number of clinical trials that have been performed to date and the lessons learned from these.
[Cancer Gene Therapy]